← All trials
NCT05243602
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2022
- Primary completion
- Jun 30, 2023
- Completion date
- Jun 30, 2023
- First posted
- Feb 17, 2022
- Last posted
- May 25, 2022
- Enrollment
- 520
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of NairobiLead sponsor
- Gilead SciencesCollaborator
- University of NairobiOverall official - principal investigator
- University of NairobiReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.